Skip to main content

Advertisement

SpringerLink
Log in

Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Vascular endothelial growth factor (VEGF) plays a crucial role in the regulation of angiogenesis and is involved in the development and metastasis of common cancers. There were several case–controls studies published to assess the associations of VEGF polymorphisms with risk of prostate cancer, but the findings were inconsistent. We performed a meta-analysis to provide a comprehensive assessment of the associations of three VEGF polymorphisms with risk of prostate cancer. The pooled odds ratio (OR) with 95 % confidence interval (95 % CI) was calculated to assess the associations. Eleven individual case–control studies with a total of 5,209 cases of prostate cancer and 5,233 controls were finally included into our meta-analysis. Overall, VEGF rs833061 polymorphism was not associated with risk of prostate cancer (T versus C, OR = 1.14, 95 % CI 0.91–1.44, P = 0.26; TT versus CC, OR = 1.09, 95 % CI 0.67–1.76, P = 0.74; TT versus CC/CT: OR = 1.46, 95 % CI 0.67–3.18, P = 0.34; TT/CT versus CC, OR = 1.08, 95 % CI 0.82–1.43, P = 0.59). VEGF rs3025039 polymorphism was also not associated with risk of prostate cancer (T versus C, OR = 1.03, 95 % CI 0.91–1.16, P = 0.66; TT versus CC, OR = 1.82 95 % CI 0.16–20.53, P = 0.63; TT versus CC/CT, OR = 2.00, 95 % CI 0.18–22.41, P = 0.57; TT/CT versus CC, OR = 0.72, 95 % CI 0.38–1.36, P = 0.31). VEGF rs2010963 polymorphism was not associated with risk of prostate cancer under three models (C versus G, OR = 1.17, 95 % CI 0.92–1.48, P = 0.20; CC versus GG, OR = 2.28, 95 % CI 0.90–5.75, P = 0.08; CC versus GG/GC, OR = 1.57, 95 % CI 0.67–3.68, P = 0.30). In conclusison, current data suggest that those three VEGF polymorphisms are not obviously associated with risk of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  3. Bikfalvi A. Angiogenesis and invasion in cancer. Handb Clin Neurol. 2012;104:35–43.

    Article  PubMed  Google Scholar 

  4. Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int. 2012;110:E794–808.

    Article  PubMed  Google Scholar 

  5. Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol. 2012;9:498–509.

    Article  PubMed  CAS  Google Scholar 

  6. Lin J, Kelly WK. Targeting angiogenesis as a promising modality for the treatment of prostate cancer. Urol Clin North Am. 2012;39:547–60.

    Article  PubMed  Google Scholar 

  7. Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 2012;33:1259–69.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  8. Giacca M, Zacchigna S. Vegf gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 2012;19:622–9.

    Article  PubMed  CAS  Google Scholar 

  9. Sfar S, Saad H, Mosbah F, Chouchane L. Synergistic effect and vegf/hsp70-hom haplotype analysis: relationship to prostate cancer risk and clinical outcome. Hum Immunol. 2010;71:377–82.

    Article  PubMed  CAS  Google Scholar 

  10. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of vegf genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35:21–8.

    Article  PubMed  CAS  Google Scholar 

  11. Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position −460 and sporadic prostate cancer in the turkish population. Mol Biol Rep. 2008;35:17–22.

    Article  PubMed  CAS  Google Scholar 

  12. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene-460 c/t polymorphism is a biomarker for prostate cancer. Urology. 2003;62:374–7.

    Article  PubMed  Google Scholar 

  13. Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer. 2008;44:1572–6.

    Article  PubMed  CAS  Google Scholar 

  14. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:972–7.

    Article  PubMed  CAS  Google Scholar 

  15. Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T, et al. Clinical implication of vascular endothelial growth factor t-460c polymorphism in the risk and progression of prostate cancer. Oncol Rep. 2007;18:1155–63.

    PubMed  CAS  Google Scholar 

  16. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.

    Article  Google Scholar 

  17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed Central  PubMed  Google Scholar 

  18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  PubMed  CAS  Google Scholar 

  19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    PubMed  CAS  Google Scholar 

  20. Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 2013;34:1895–9.

    Article  PubMed  CAS  Google Scholar 

  21. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943–8.

    Article  PubMed  CAS  Google Scholar 

  22. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62:3369–72.

    PubMed  CAS  Google Scholar 

  23. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor snps as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8:2496–508.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  24. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, et al. Interaction among variant vascular endothelial growth factor (vegf) and its receptor in relation to prostate cancer risk. Prostate. 2010;70:341–52.

    PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, Second Hospital of Longyan City, Longyan, 364000, Fujian Province, China

    Guo-Qiang Chen, Jian-bin Luo, Guang-Zhi Wang & Jin-E Ding

Authors
  1. Guo-Qiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian-bin Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang-Zhi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin-E Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guo-Qiang Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, GQ., Luo, Jb., Wang, GZ. et al. Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer. Tumor Biol. 35, 1875–1879 (2014). https://doi.org/10.1007/s13277-013-1250-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1250-9

Keywords

Search

Navigation